Showing 3501-3510 of 7262 results for "".
- New From InMode: Triton Multi-Wavelength Hair Removal Laserhttps://practicaldermatology.com/news/new-from-inmode-triton-multi-wavelength-hair-removal-laser/2457698/InMode Ltd. is launching the Triton hair removal device. Recently cleared by the FDA, Triton is the first and only high power laser to offer simultaneous multi-wavelength hair removal firing, allowing concurrent emissions of Alexandrite, Diode, and Nd:YAG wavelengths. The company say
- About 415 Million People May Have Rosacea Worldwidehttps://practicaldermatology.com/news/about-415-million-people-may-have-rosacea-worldwide/2457701/As many as 415 million people worldwide may have rosacea, according to new research in the British Journal of Dermatology. Dr. Jacob Thyssen and colleagues at the University of Copenhagen, Denmark, conducted
- Dermtech's Noninvasive Melanoma Screen Improves Care, Lowers Costhttps://practicaldermatology.com/news/dermtechs-noninvasive-melanoma-screen-improves-care-lowers-cost/2457700/New research shows that DermTech’s Pigmented Lesion Assay (PLA) reduces cost while improving the care of patients with primary pigmented skin lesions suggestive of melanoma. The
- Nanotechnology May Improve Onychomycosis, Cut Costshttps://practicaldermatology.com/news/nanotechnology-may-improve-onychomycosis-cut-costs/2457702/Nanotechnology can improve efinaconazole treatment for onychomycosis and make it more cost effective, according to new research in the Journal of Drugs in Dermatology.
- Life Sciences Industry Eyes $1.5 Trillion Milestonehttps://practicaldermatology.com/news/life-sciences-industry-eyes-15-trillion-milestone/2457703/The life sciences industry is nearing a $1.5 trillion milestone, according to an analysis from Frost & Sullivan. The firm’s Global Life Sciences Industry Outlook, 2018 report finds that healthcare digitization and consumerization, the explosion of patient data, and the emergence of
- XELJANZ Receives EU Marketing Authorization for Adults with Active PsAhttps://practicaldermatology.com/news/xeljanz-receives-eu-marketing-authorization-for-adults-with-active-psa/2457706/The European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-mod
- PAH after Cryolipolysis May Not Be So 'Rare'https://practicaldermatology.com/news/pah-after-cryolipolysis-may-not-be-so-rare/2457707/Paradoxical adipose hyperplasia (PAH) after cryolipolysis may be more common than previously thought according to a paper in the July issue of Plastic and Reconstructive Surgery®. While PAH can be treated successfully
- FDA Approves Braftovi in Combination with Mektovi for Advanced BRAF-mutant Melanomahttps://practicaldermatology.com/news/fda-approves-of-braftovi-in-combination-with-mektovi-for-advanced-braf-mutant-melanoma/2457710/The FDA has approved Array BioPharma Inc.'s BRAFTOVI (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by a
- World Vitiligo Day: Ra Medical Highlights Potential of Technologyhttps://practicaldermatology.com/news/world-vitiligo-day-pharos-highlights-potential-of-technology/2457715/In light of World Vitiligo Day (June 25), it’s important to realize that hope is here for patients who suffer from this disease, says Ra Medical Systems. Painless treatment is a possibility with P
- Alana Sine is New CFO at Merz North Americahttps://practicaldermatology.com/news/alan-sine-is-new-cfo-at-merz-north-america/2457719/Merz North America has appointed Alana Sine as Chief Financial Officer (CFO), Merz North America. Ms. Sine has served as interim CFO since March 2018. Ms. Sine will lead the finance function for North America, overseeing finan